Risk factor
High price volatility
Profitability factor
Very strong margins and returns
About
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair
Target Price
The average target price of NEU.AX is 24 and suggests 46% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell